B

BioMarin Pharmaceutical
D

BMRN

61.490
USD
-1.10
(-1.75%)
مفتوح الان
حجم التداول
3,058
الربح لكل سهم
3
العائد الربحي
-
P/E
47
حجم السوق
11,706,639,725
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار

العنوان: BioMarin Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.